1.Impact of a focused solution-oriented short-term intervention combined with social skills training based on WeChat on discharged schizophrenic patients
Lingya MA ; Liang CAI ; Guihong WU
China Modern Doctor 2024;62(32):21-24
Objective To investigate the effect of focused solution-oriented short-term intervention combined with social skills training based on WeChat on the recovery of discharged schizophrenia patients.Methods A total of 200 schizophrenia patients discharged from Shaoxing Seventh People's Hospital from January 2022 to December 2023 were selected as study subjects,and divided into study group and control group by random number table,with 100 patients in each group.During the course of the study,11 and 29 cases were lost in study group and control group,respectively,and finally 89 cases were in study group and 71 cases in control group.The control group received routine post-discharge follow-up,while the study group received a 6-month intervention focused solution-oriented short-term intervention combined with social skills training based on WeChat.Before and after the intervention,the positive and negative syndrome scale(PANSS),stigma scale for mental illness(SSMI-C),morning side rehabilitation stats scale(MRSS),and adherence to medication were assessed.Results After the intervention,the total scores of PANSS,SSMI-C,and MRSS in study group were significantly lower than those in control group,and the adherence to medication was higher than that in control group,with statistically significant differences(P<0.05).Conclusion Focused solution-oriented short-term intervention combined with social skills training based on WeChat can reduce the stigma of mental illness in discharged schizophrenia patients,improve their adherence to medication,stabilize their condition,and play a positive role in promoting their recovery.
2.Embryo-fetal developmental toxicity and toxicokinetics of fluoropezil in New Zealand rabbits
Shanshan MAO ; Fang LI ; Guihong CAI ; Yunkai ZHU ; Xu XU ; Yanjun CUI ; Wen ZHOU ; Min CAO ; Li ZHOU
Chinese Journal of Pharmacology and Toxicology 2024;38(2):120-127
OBJECTIVE To study the effect of fluoropezil on embryo-fetal developmental toxicity and toxicokinetics in rabbits,and provide reference for clinical medication.METHODS According to the sequence of pregnancy,pregnant rabbits were divided into five groups:vehicle control group(1%hydroxy-propyl methylcellulose+1.5%polyethylene glycol 400 aqueous solution),positive control group(cyclo-phosphamide 18 mg·kg-1),and fluoropezil(3.6,9.0 and 22.5 mg·kg-1)groups.The vehicle control group and the fluoropezil groups were ig administrated on the 6th to 18th day of gestation(GD6-18)while the positive control group was ig given cyclophosphamide on GD6-20.The pregnant rabbits were sacri-ficed on GD28,and the embryo-fetal development was detected.Sex hormone levels of pregnant rabbits on GD5,GD18 and GD28 were detected by ELISA method.Blood samples with toxokinetics were collected for concomitant toxic generation at the first and last administration,and drug concentrations in fetal,placenta and amniotic fluid were detected with liquid chromatography tandem mass spectrometry(LC-MS/MS).RESULTS Fluoropezil 3.6,9.0 and 22.5 mg·kg-1 had no significant effect on body mass,mass gain,food consumption,pregnancy outcomes,fetal appearance,viscera,skeletal and physical growth and development of pregnant rabbits.Only on GD18 or GD28,the levels of follicle stimulating hormone,estra-diol and progesterone in each dose group fluctuated to some extent.The combined toxokinetics results indicated that fluoropezil could cross the placental barrier of the rabbits,but did not accumulate in preg-nant rabbits or fetuses.Fetal mass,crown-rump length and uterus mass in the cyclophosphamide group were lower than those in the vehicle control group.The appearance and bone of the cyclophos-phamide group were positive.CONCLUSION The no observed adverse effect level(NOAEL)of fluoro-pezil toxicity on rabbit embryo-fetal development is 22.5 mg·kg-1,which is 125 times of the effective dose.At the dosage level of 22.5 mg·kg-1,Cmax is 1093 μg·L-1,and AUC(0-24 h)6650 μg·h·L-1 on GD18.
3.Herbal textual research on Flos Trollii
Hongye CAI ; Jin WU ; Xuelian WANG ; Guihong WANG ; Zhilai ZHAN ; Guohua ZHENG ; Junjie HU
China Pharmacy 2023;34(21):2678-2683
Flos Trollii is a traditional Chinese medicinal herb in China. The 2020 edition of the Chinese Pharmacopoeia (part 1) did not include the medicinal herb, its source is not clear, and there is a lack of relevantly systematic and comprehensive research. By consulting ancient Chinese herbal medicines, medical books and related literature, the textual research of Flos Trollii was conducted to verify the name, origin and producing area, so as to provide a reference for the clinical application and resource development of Flos Trollii. Through textual research, it could be seen that the name “Jinlianhua” was used as the correct name in the mainstream origin of the past dynasties, and there were still multiple synonyms such as Hanjinlian, Jinmeicao and so on, most of which originated from its growth environment and appearance. According to the distribution of varieties, it could be inferred that the mainstream origin of Flos Trollii in the Qing Dynasty and before was Trollius chinensis Bge. According to historical records, Flos Trollii were mostly produced in northern regions such as Hebei, Inner Mongolia, Shanxi, etc., which was related to the fact that Flos Trollii liked cloudy, humid and cold environments. Based on the textual research results, the author suggested that the mainstream origin of the past dynasties T. chinensis Bge. should be selected for subsequent collection of Flos Trollii.